Clinical Trial Update: Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention [Phase 2]

View source ↗

Summary

A Phase II clinical trial to evaluate HRS-9057 Injection for fluid retention caused by heart failure is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• HRS-9057 Injection (HRS-9057)

Snippet

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Conditions: Fluid Retention Caused by Heart Failure | Phase 2 | Status: RECRUITING